Precigen Clinical Pipeline and Partnered Programs
As of January 14, 2020
Precigen Preclinical Pipeline
Our growing pipeline of multifunctional gene and cell therapy candidates gives us distinct advantages for combination strategies. Our preclinical and clinical pipeline includes several programs leveraging our platform technologies in our core therapeutic areas: immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen and Novartis are collaborating on CGF166, a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1). CGF166 is currently under clinical investigation to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through IL-infusion to improve hearing. Please visit clinicaltrials.gov for additional information regarding this clinical study.